Stories

Expert Voices

Putting a price on new cancer treatments

Laz Gamio / Axios

Last week, the FDA approved a new immunotherapy for treating a type of leukemia that affects children and young adults. The manufacturer, Novartis, expects it will cost about $475,000 for the one-time personalized treatment in which a patient's immune cells are removed, modified so they attack cancer cells and then infused back into the body. Other companies are working on similar therapies for other cancers —with tentative success and serious setbacks.

As these new drugs begin to enter the market, we asked researchers, economists and policy experts: how should their value be determined? Their answers:

More stories loading.